Abstract
DuoBody-PD-L1×4-1BB, a first-in-class, bispecific, next-generation checkpoint immunotherapy activates T cells through conditional 4-1BB costimulation and simultaneously blocks the PD-L1 axis. Here we present dose-escalation data from the ongoing, first-in-human, open-label, phase I/IIa trial (NCT03917381) of DuoBody-PD-L1×4-1BB in advanced solid tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
